Thanks Capt. Is this the new form that will require less caps per day? Bioequivalence worries me because isn’t that what GV had to show? A equivalent to B and B equivalent to C would mean A equivalent to C.
Nightmare would be if insurance cos and PBM would sub GV for it. But can I assume the new patent would take care of that?
Market Data 
Markets 
AI
